Table 2.

Comparison of demographic and clinical features in SLE patients with pulmonary arterial hypertension versus those without.

	SLE patients with PAH (N = 8, 10.8%)	SLE patients without PAH (N = 66, 89.2%)	P value#
Age (yr)
Range	12–30	11–45	0.4
Mean ± SD	23.50 ± 5.95	25.93 ± 8.14
Age at onset of the disease (yr)
Range	11.7–29	10–37.5	0.9
Mean ± SD	21.53 ± 5.97	21.54 ± 6.76
Duration of the disease (yr)
Range	0.3–6	0.1–16	0.05
Mean ± SD	1.98 ± 1.86	4.39 ± 3.42
Fever	2 (25%)	25 (37.9%)	0.7
Malar rash	7 (87.5%)	54 (81.8%)	1
Photosensitivity	6 (75%)	51 (77.3%)	1
Alopecia	6 (75%)	42 (63.6%)	0.7
Oral ulcers	5 (62.5%)	48 (72.7%)	0.7
Raynaud’s phenomenon	5 (62.5%)	18 (27.3%)	0.1
Arthralgia	7 (87.5%)	63 (95.5%)	0.4
Arthritis	5 (62.5%)	51 (77.3%)	0.4
Myalgia	5 (62.5%)	46 (69.7%)	0.7
Pleurisy	0	11 (16.7%)	0.6
Renal affection
Proteinuria	2 (25%)	34 (51.5%)	0.1
Casts	1 (12.5%)	24 (36.4%)	0.1
Eye affection	0	1	1
SLEDAI
Range	6–24	0–39	0.2
Mean ± SD	12.50 ± 5.55	17.18 ± 8.93

Note:

^#Chi-squared or Student’s t-test.

Abbreviations: PAH, pulmonary arterial hypertension; SLEDAI, SLE disease activity index.